General Announcement::Glenmark becomes the First Pharmaceutical Company to launch Teneligliptin and Pioglitazone

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
25-Apr-2022 13:46:08
Status
New
Announcement Sub Title
Glenmark becomes the First Pharmaceutical Company to launch Teneligliptin and Pioglitazone
Announcement Reference
SG220425OTHRGO6U
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
25/04/2022 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark becomes the First Pharmaceutical Company to launch Teneligliptin + Pioglitazone Fixed-Dose Combination Drug
for Type 2 Diabetes in India

Attachments

SGX_PR_25042022.pdf
Total size =954K